BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

...cancer company Samumed LLC as CSO. He was CSO for tumor biology at the pharma. EpicentRx Inc....
...Sawka, BioCentury Staff Ferring Pharmaceuticals Inc. Samumed LLC Immatics Biotechnologies GmbH ImmunoGen Inc. Aligos Therapeutics Inc. Sanifit Spectrum Pharmaceuticals Inc. Prevail Therapeutics Inc. AxoGen Inc. EpicentRx Inc. Lonza...
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...Francisco office. Ciechanover was president and CEO of Atara Biotherapeutics Inc. (NASDAQ:ATRA), which he founded. EpicentRx Inc....
...back to the immuno-oncology company's November $35 million series D (see "With $35M D Round, EpicentRx...
BioCentury | Nov 13, 2019
Financial News

With $35M D round, EpicentRx aims to complete clinical testing of cancer immunotherapy

...With a $35 million series D, EpicentRx hopes to take its immunotherapy through to an NDA...
...the sole investor in the round, which will be split into three tranches and give EpicentRx Inc....
...of runway, President and CEO Corey Carter told BioCentury. Launched in 2002, La Jolla, Calif.-based EpicentRx...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...NASDAQ:HOOK) hired Christine Baker as CBO and Roman Necina as CTO. Baker was CBO at EpicentRx Inc....
BioCentury | Sep 7, 2015
Clinical News

RRx-001: Phase I data

...colorectal cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and neuroendocrine tumors. EpicentRx Inc....
Items per page:
1 - 5 of 5
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

...cancer company Samumed LLC as CSO. He was CSO for tumor biology at the pharma. EpicentRx Inc....
...Sawka, BioCentury Staff Ferring Pharmaceuticals Inc. Samumed LLC Immatics Biotechnologies GmbH ImmunoGen Inc. Aligos Therapeutics Inc. Sanifit Spectrum Pharmaceuticals Inc. Prevail Therapeutics Inc. AxoGen Inc. EpicentRx Inc. Lonza...
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...Francisco office. Ciechanover was president and CEO of Atara Biotherapeutics Inc. (NASDAQ:ATRA), which he founded. EpicentRx Inc....
...back to the immuno-oncology company's November $35 million series D (see "With $35M D Round, EpicentRx...
BioCentury | Nov 13, 2019
Financial News

With $35M D round, EpicentRx aims to complete clinical testing of cancer immunotherapy

...With a $35 million series D, EpicentRx hopes to take its immunotherapy through to an NDA...
...the sole investor in the round, which will be split into three tranches and give EpicentRx Inc....
...of runway, President and CEO Corey Carter told BioCentury. Launched in 2002, La Jolla, Calif.-based EpicentRx...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...NASDAQ:HOOK) hired Christine Baker as CBO and Roman Necina as CTO. Baker was CBO at EpicentRx Inc....
BioCentury | Sep 7, 2015
Clinical News

RRx-001: Phase I data

...colorectal cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and neuroendocrine tumors. EpicentRx Inc....
Items per page:
1 - 5 of 5